Navigation Links
OncoGenex Reports Third Quarter 2009 Financial Results
Date:11/5/2009

eptember 30, 2009 general and administrative expenses increased to $2.7 million from $2.2 million in 2008. The increase in 2009 was primarily due to increased employee expenses and increased costs associated with operating as a public company.

The net loss for the third quarter increased to $2.4 million from $4.6 million in income in 2008. For the nine months ended September 30, 2009 the net loss increased to $9.4 million from $0.8 million in income in 2008. The net income recognized in both 2008 periods was primarily due to the impact of an extraordinary gain on the reverse takeover of Sonus and a reversal of tax expense associated with the change in capital structure of OncoGenex Technologies, both non-cash items.

The third quarter and nine months ended September 30, 2008 also included $0.4 million and $2.0 million, respectively, in preferred share accretion, a non-cash item, which did not recur in the third quarter or nine months ended September 30, 2009, as subsequent to the reverse takeover there are no preferred shares outstanding.

The Company had $12.5 million in cash, cash equivalents and short-term investments as of September 30, 2009, compared to $12.4 million in cash, cash equivalents and short-term investments as of December 31, 2008.

The Company had 6,034,959 shares outstanding as of November 1, 2009. The Company believes that its cash, cash equivalents and short-term investments will be sufficient to fund its currently planned operations through at least the third quarter of 2010, including:

    -   completing partnering discussions related to OGX-011;
    -   completing follow-up monitoring visits related to completed phase 2
        clinical trials of OGX-011;
    -   completing follow-up monitoring visits related to the Phase 1
        clinical trial evaluating OGX-427 as a monotherapy in patients with
        solid tumors and continuing evaluation of OGX-427 in combination with
        docetaxe
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... are intensively investigated for application as catalysts, ... and components in photonics and molecular electronics. ... for understanding physical and chemical properties, has ... USA, have demonstrated that high-resolution electron microscopy ... structure in which all gold atoms are ...
(Date:8/22/2014)... Aug. 22, 2014 Research and Markets ... and China Gel Permeation Chromatography (GPC) Industry Report 2014" ... Global and China Gel Permeation Chromatography (GPC) Industry Report ... state of the global gel permeation chromatography industry with ... provides a basic overview of the industry including definitions, ...
(Date:8/22/2014)... Los Angeles (PRWEB) August 22, 2014 ... for age-defying products, is in the spotlight again. ... night cream and its NeriumFirmTM Body Contouring Cream ... presented by Backstage Creations during the 66th Primetime ... the patented NAE-8® extract, third-party clinical trials show ...
(Date:8/21/2014)... N.Y. , Aug. 21, 2014  BioSpecifics ... biopharmaceutical company developing first in class collagenase-based products ... or CCH) in the U.S. and XIAPEX ® ... significant results from a randomized, double-blind Phase 2a ... cellulite, or edematous fibrosclerotic panniculopathy. The results showed ...
Breaking Biology Technology:A breakthrough in imaging gold nanoparticles to atomic resolution by electron microscopy 2Global and China Gel Permeation Chromatography (GPC) Industry Report 2014 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5
... communications system. Image courtesy of GE Healthcare. Wisconsin ... include $10 million for a grant and loan program ... systems. , ,"I am committed to ensuring that all ... why I am pleased to unveil a proposal of ...
... and Minnesota students will get a one-of-a-kind experience today ... the International Space Station Expedition 10 crew. , ,The ... EST today at Crossroads Elementary School, St. Paul, Minn. ... Leroy Chiao and Flight Engineer Salizhan Sharipov. Nearly 700 ...
... human embryos. , ,This weeks announcement out of Kings ... the sheep, has been granted a license by the British ... hopes among disease sufferers, scientists and advocacy groups for a ... (ALS). , ,These diseases could be addressed through research on ...
Cached Biology Technology:Doyle proposes $10M to expand use of electronic medical records 2Doyle proposes $10M to expand use of electronic medical records 3Human cloning plans get blessing from British government 2Human cloning plans get blessing from British government 3
(Date:8/21/2014)... previously unknown process for harvesting energy and producing oxygen ... State University scientist has discovered. The discovery lays the ... harvesting energy from the Sun, and understanding dense blooms ... lakes worldwide. A paper describing the discovery will be ... the journal Science on 21 August 2014. ...
(Date:8/21/2014)... A ubiquitous skin fungus linked to dandruff, eczema and ... tracked to even further global reachesincluding Hawaiian coral reefs ... sea vents. , A review in the scientific journal ... distribution of the fungi of the genus Malassezia ... environmental sequencing datasets from around the world. , University ...
(Date:8/21/2014)... intake, health and quality of life of older adults ... the University of Waterloo receiving close to $1.5 million ... (CIHR). , Professor Heather Keller, of the Faculty ... research chair in nutrition and aging, will receive $979,000 ... in long-term care homes are poorly nourished. The project ...
Breaking Biology News(10 mins):Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2Grants will fund landmark aging research at Waterloo 2
... will take place on the campus of the Abdus ... the Academy,s secretariat. TWAS,s new executive director, Romain Murenzi, ... of TWAS; Fernando Quevedo, director of ICTP; Immacolata Pannone, ... TWAS President, will highlight the opening ceremony. The morning ...
... 15, 2011   DigitalPersona, Inc. ... protection solutions, today announced at the CARTES & ... company has open sourced its new MINEX-certified FingerJetFX™ ... (OSE), is free, portable software that device manufacturers ...
... FRANCISCO, CANovember 15, 2011The American Heart Association will ... Emeritus Robert Mahley, MD, PhD, with the 2011 ... on one of Gladstone,s founding cardiovascular scientists. ... that the American Heart Association can give a ...
Cached Biology News:TWAS 22nd General Meeting in Trieste 2DigitalPersona Open Sources New FingerJetFX Biometrics Technology for Mobile Devices, PCs and Servers 2DigitalPersona Open Sources New FingerJetFX Biometrics Technology for Mobile Devices, PCs and Servers 3Gladstone founder receives American Heart Association Distinguished Scientist Award 2
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
...
... kits are designed to rapidly and ... using our patented APA Technology. APAgene ... an extraordinarily competitive price. All necessary ... The Locator Kit can be used ...
... designed to deparaffinize and perform Heat Induced ... tissue sections mounted on glass microscope slides. ... at the high temperature used in HIER ... the paraffin by detergent. Formaldehyde fixation impairs ...
Biology Products: